US 11,938,126 B2
Method of treating diseases of the visual system
Jonnie R. Williams, Sarasota, FL (US)
Assigned to MyMD Pharmaceuticals, Inc., Baltimore, MD (US)
Filed by MyMD Pharmaceuticals, Inc., Baltimore, MD (US)
Filed on Jun. 28, 2022, as Appl. No. 17/851,862.
Application 17/851,862 is a division of application No. 17/524,304, filed on Nov. 11, 2021.
Application 17/524,304 is a continuation of application No. 16/928,255, filed on Jul. 14, 2020, granted, now 11,219,620, issued on Jan. 11, 2022.
Application 16/928,255 is a continuation in part of application No. 16/680,677, filed on Nov. 12, 2019, granted, now 11,179,382, issued on Nov. 23, 2021.
Application 16/680,677 is a continuation of application No. 15/719,875, filed on Sep. 29, 2017, granted, now 10,517,856, issued on Dec. 31, 2019.
Application 15/719,875 is a continuation in part of application No. PCT/US2016/025126, filed on Mar. 31, 2016.
Claims priority of provisional application 62/140,618, filed on Mar. 31, 2015.
Prior Publication US 2022/0339147 A1, Oct. 27, 2022
Int. Cl. A61K 31/465 (2006.01); A61K 8/49 (2006.01); A61K 31/4439 (2006.01); A61P 3/08 (2006.01); C07K 14/47 (2006.01)
CPC A61K 31/465 (2013.01) [A61K 8/4926 (2013.01); A61K 31/4439 (2013.01); A61P 3/08 (2018.01); C07K 14/4747 (2013.01); Y02A 50/30 (2018.01)] 10 Claims
OG exemplary drawing
 
1. A method of treating a disease of the visual system selected from the group consisting of uveitis, glaucoma, and age-related macular degeneration (AMD), the method comprising administering to an individual in need thereof a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable vehicle thereof.